ITCIのチャート
ITCIの企業情報
symbol | ITCI |
---|---|
会社名 | Intra-Cellular Therapies Inc (イントラセルラ―・セラピ―ズ) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Major Pharmaceuticals |
業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連(Health Care) |
概要 | 事業概要 イントラ・セルラー・セラピーズ(Intra-Cellular Therapies Inc.)はバイオ医薬品会社である。同社は中枢神経系(CNS)内の細胞内シグナル伝達機構を標的とすることにより、神経精神医学的および神経学的障害における不十分な医学的ニーズに対処する小分子薬物の発見・臨床開発を行う。同社は神経学的および精神医学的障害の治療のための薬物を発見・開発する。ルマテペロン(ITI-007)は、主要製品候補である。同社の双極性うつ病プログラムは、2つの第III相多施設、無作為化、二重盲検、プラセボ対照臨床試験で構成される。1つは単独治療としてルテテペロンを評価し、もう1つはリチウムまたはバルプロエートによる補助療法としてルテテペロンを評価する。同社は、アルツハイマー病(AD)を含む認知症患者の激越の治療のためのルテテペロンの第III相開発を開始した。 イントラセルラ―・セラピ―ズは、米国のバイオ製薬企業。中枢神経系内の細胞内シグナル伝達機構を標的とする神経精神障害および神経障害に対処する小分子薬の発見と臨床開発に焦点を当てる。主要製品候補は、統合失調症のためのファ―ストインクラスの治療薬「ITI-007」、統合失調症および認知障害の治療薬「 ITI-002」がある。 Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. |
本社所在地 | 430 East 29th Street New York NY 10016 USA |
代表者氏名 | Lawrence J. Hineline ローレンスJ.ヒネリン |
代表者役職名 | Chief Financial Officer Vice President - Finance Treasurer Assistant Secretary |
電話番号 | +1 212-923-3344 |
設立年月日 | 41122 |
市場名 | NASDAQ National Market System |
ipoyear | ―年 |
従業員数 | 49人 |
url | www.intracellulartherapies.com |
nasdaq_url | https://www.nasdaq.com/symbol/itci |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -132.42960 |
終値(lastsale) | 18.42 |
時価総額(marketcap) | 1007744790.24 |
時価総額 | 時価総額(百万ドル) 996.25590 |
売上高 | 売上高(百万ドル) 0.03581 |
企業価値(EV) | 企業価値(EV)(百万ドル) 592.49140 |
当期純利益 | 当期純利益(百万ドル) -127.03560 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Intra-Cellular Therapies Inc revenues decreased from $210K to $0K. Net loss increased 63% to $72.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 91% to $59.3M (expense) General and administrative - Balancing v increase of 20% to $8.3M (expense). |
ITCIのテクニカル分析
ITCIのニュース
Intra-Cellular Therapies Has My Attention 2022/11/30 15:28:48 The Street RealMoney
We have two price targets….ITCI
Analysts Predict An Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Spike? 2022/11/19 12:30:00 Stocks Register
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares, rose in value on Friday, 11/18/22, with the stock price up by 2.63% to the previous day’s close as strong demand from buyers drove the stock to $51.94. Actively observing the price movement in the last trading, the stock closed the session at $50.61, falling within a range of $50.39 … Analysts Predict An Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Spike? Read More »
Intra-Cellular Therapies Inc. (ITCI) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/11 14:16:00 US Post News
A share of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) closed at $50.67 per share on Thursday, up from $50.01 day before. While Intra-Cellular Therapies Inc. has overperformed by 1.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ITCI rose by 17.81%, with highs and lows ranging from $66.00 […]
Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences 2022/11/10 13:00:00 GlobeNewswire
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor conferences:
Intra-Cellular Therapies, Inc. (ITCI) Q3 2022 Earnings Call Transcript 2022/11/03 18:42:05 Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:NASDAQ:ITCI) Q3 2022 Earnings Conference Call November 03, 2022, 08:30 ET Company Participants Juan Sanchez - VP, Corporate Communications & IR…
SILVERARC CAPITAL MANAGEMENT, LLC Buys 4, Sells 1 in 3rd Quarter 2022/10/29 03:00:05 GuruFocus
Related Stocks: ITCI , PSTX , PRTA , ALNY , VRAY ,
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast 2022/10/27 12:00:00 GlobeNewswire
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 3, 2022, to provide a corporate update and discuss details of the Company''s financial results for the quarter ended September 30, 2022.
Intra-Cellular Therapies: What Lies Ahead (NASDAQ:ITCI) 2022/09/20 23:45:38 Seeking Alpha
Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Click here to read an investment analysis.
Looking Into Intra-Cellular Therapies''s Return On Capital Employed 2022/09/02 14:25:59 Benzinga
Intra-Cellular Therapies (NASDAQ: ITCI ) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 20.08%, resulting in a loss of $86.60 million. Intra-Cellular Therapies collected $35.00 million in revenue during Q1, but reported earnings showed a $72.12 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug 2022/08/22 16:07:09 Seeking Alpha
Goldman Sachs downgraded commercial-stage biopharma Intra-Cellular Therapies, Inc
Intra-Cellular Therapies: What Lies Ahead (NASDAQ:ITCI) 2022/09/20 23:45:38 Seeking Alpha
Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Click here to read an investment analysis.
Looking Into Intra-Cellular Therapies''s Return On Capital Employed 2022/09/02 14:25:59 Benzinga
Intra-Cellular Therapies (NASDAQ: ITCI ) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 20.08%, resulting in a loss of $86.60 million. Intra-Cellular Therapies collected $35.00 million in revenue during Q1, but reported earnings showed a $72.12 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug 2022/08/22 16:07:09 Seeking Alpha
Goldman Sachs downgraded commercial-stage biopharma Intra-Cellular Therapies, Inc
Goldman Sachs Downgrades Intra-Cellular Therapies to Neutral 2022/08/22 06:05:06 Investing.com
https://www.investing.com/news/pro/goldman-sachs-downgrades-intracellular-therapies-to-neutral-432SI-2877078
Director Of Intra-Cellular Therapies Makes $592K Sale 2022/08/15 14:45:34 Benzinga
Joel S Marcus , Director at Intra-Cellular Therapies (NASDAQ: ITCI ), reported a large insider sell on August 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Marcus sold 10,000 shares of Intra-Cellular Therapies . The total transaction amounted to $592,200. Intra-Cellular Therapies shares are trading down 3.77% at $51.55 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to … Full story available on Benzinga.com